昆山亚香香料股份有限公司 2024 年度独立董事述职报告 (王俊) 各位股东及股东代表： 作为昆山亚香香料股份有限公司（以下简称"公司"）的独立董事，2024 年度， 本人严格按照《公司法》、《证券法》、《上市公司治理准则》、《上市公司独 立董事规则》等法律法规和《公司章程》的有关规定，忠实履行独立董事的职责， 谨慎、认真、勤勉地行使公司所赋予独立董事的权利，积极出席公司相关会议， 认真审议各项议案，对公司的相关事项发表了独立意见，较好地维护了公司和股 东特别是中小股东的合法权益。现就本人 2024 年度履行职责情况述职如下： 一、独立董事基本情况 王俊，男，1967 年 7 月出生，中国国籍，无境外永久居留权，化学专业大学 专科学历，高级工程师。1987 年至 1993 年，任上海黄浦仪器厂技术研发助理工 程师；1994 年至 2000 年，任上海新华香料厂质量监督科科长；2000 年至 2007 年，任滕州悟通香料有限公司董事兼副总经理；2007 年至 2013 年，任北京北大 正元科技有限公司技术总监；2013 年至 2015 年，任四川鼎世生物科技有限公司 总工程师；2015 年至 2018 年，任南 ...

昆山亚香香料股份有限公司 昆山亚香香料股份有限公司 董事会对独立董事独立性评估的专项报告 根据证监会《上市公司独立董事管理办法》、《深圳证券交易所创业板股票上市 规则》、《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运 作》等要求，昆山亚香香料股份有限公司（以下简称"公司"）董事会，就公司在任 独立董事刘文先生、王俊先生，李群英女士的独立性情况进行评估并出具如下专项意 见： 经核查独立董事刘文先生、王俊先生、李群英女士的任职经历以及签署的相关自 查文件，上述人员未在公司担任除独立董事以外的任何职务，也未在公司主要股东公 司担任任何职务，与公司以及主要股东之间不存在利害关系或其他可能妨碍其进行独 立客观判断的关系，不存在影响独立董事独立性的情况。因此，公司独立董事符合 《上市公司独立董事管理办法》、《深圳证券交易所上市公司自律监管指引第 2 号— —创业板上市公司规范运作》中对独立董事独立性的相关要求。 董事会 2025 年 4 月 23 日 ...

2024 年度独立董事述职报告 (李群英) 各位股东及股东代表： 作为昆山亚香香料股份有限公司（以下简称"公司"）的独立董事，2024 年 度，本人严格按照《公司法》、《证券法》、《上市公司治理准则》、《上市公 司独立董事规则》等法律法规和《公司章程》的有关规定，忠实履行独立董事的 职责，谨慎、认真、勤勉地行使公司所赋予独立董事的权利，积极出席公司相关 会议，认真审议各项议案，对公司的相关事项发表了独立意见，较好地维护了公 司和股东特别是中小股东的合法权益。现就本人 2024 年度履行职责情况述职如 下： 一、独立董事基本情况 本人李群英，女，1981 年 2 月出生，中国国籍，无境外永久居留权，民商法 专业硕士，执业律师。2005 年至 2006 年，任河南邮政职员；2006 年至 2010 年， 任昆山华德宝科盈扶梯设备有限公司人事行政经理；2010 年至 2013 年，任昆山 柯斯美光电有限公司副总经理；2021 年 4 月至今，任上海合鸿律师事务所创始 合伙人。2019 年 3 月至今，任亚香股份独立董事，本人未在公司担任除独立董 事外的其他职务。 二、是否存在影响独立性的情况说明 作为公司独立董事， ...

Financial Performance - The company's operating revenue for 2024 reached ¥796,682,291.89, representing a 26.42% increase compared to ¥630,177,917.19 in 2023[20]. - The net profit attributable to shareholders decreased by 30.51% to ¥55,702,989.79 in 2024 from ¥80,158,022.75 in 2023[20]. - The cash flow from operating activities net amount was ¥31,323,296.98, down 58.75% from ¥75,931,894.12 in the previous year[20]. - Basic earnings per share fell by 31.00% to ¥0.69 in 2024, compared to ¥1.00 in 2023[20]. - Total assets increased by 14.44% to ¥2,104,809,521.16 at the end of 2024, up from ¥1,839,185,281.42 at the end of 2023[20]. - The company reported a decrease in the weighted average return on net assets to 3.47% in 2024 from 5.11% in 2023, a decline of 1.64%[20]. - The gross profit margin for the flavor and fragrance manufacturing segment was 25.52%, down 6.65% from the previous year[82]. - The company achieved a total revenue of ¥796,682,291.89 in 2024, representing a year-on-year growth of 26.42%[80]. - The net profit attributable to shareholders was ¥55,702,989.79, a decrease of 30.51% compared to the previous year, primarily due to intensified product price competition[72]. Dividend and Capital Increase - The company plans to distribute a cash dividend of 2 RMB per 10 shares to all shareholders, based on a total of 79,927,100 shares[3]. - The company will increase its capital reserve by converting 4 shares for every 10 shares held by shareholders[3]. - The total cash dividend, including other methods, accounts for 100% of the total profit distribution amount[187]. - The company will also increase its capital stock by 4 shares for every 10 shares held, resulting in a total capital increase of 31,970,840 shares[189]. Market and Industry Outlook - The company plans to expand its market presence, targeting a revenue growth in the fragrance and flavor industry, projected to reach ¥50 billion by 2025[30]. - The global flavor and fragrance market size reached approximately $30.6 billion in 2023, with a year-on-year growth of 2.3%, and is expected to increase to $32.1 billion by 2025[38]. - The Chinese flavor and fragrance industry market size was about 43.9 billion yuan in 2023, reflecting a year-on-year growth of 2.6%, and is projected to exceed 50 billion yuan by 2026[40]. - The industry is experiencing a trend of increasing demand driven by rising consumer income and preferences for diverse and healthy products[37]. - The young consumer demographic (ages 18-35) in China, approximately 550 million strong, is driving demand for unique and high-quality fragrance products, influencing market diversification[50]. Research and Development - The company is focusing on research and development of new products to enhance its competitive edge in the fragrance industry[30]. - The company has developed over 310 products across three main series: natural flavors, synthetic flavors, and cooling agents, establishing a strong market presence[54]. - The company has achieved ISO9001:2015 and ISO22000:2018 certifications, ensuring high-quality standards and food safety compliance for its products[57]. - The company holds 3 authorized patents for Isopentyl Acetate and has a dedicated R&D center to ensure market-driven innovation[62]. - The company has 7 authorized patents for WS-23, with a strong emphasis on project-based R&D management to align innovations with market needs[62]. Risk Management - The report emphasizes the importance of risk awareness regarding forward-looking statements related to future plans and performance forecasts[3]. - The company has outlined potential risks in its future development outlook section[3]. - The supply of natural raw materials for the flavor and fragrance industry is subject to climate conditions and ecological protection policies, leading to potential instability[35]. Corporate Governance - The company has a total of 9 board members, including 3 independent directors, complying with legal and regulatory requirements[132]. - The company has implemented a strict financial accounting system, enabling independent financial decision-making without shared bank accounts with the controlling shareholder[140]. - The company has maintained a transparent information disclosure process, ensuring all shareholders have equal access to information[136]. - The company has established a sound internal management structure, ensuring independent exercise of management authority[141]. Employee and Management - The total number of employees at the end of the reporting period is 719, with 166 in the parent company and 553 in major subsidiaries[180]. - The professional composition includes 400 production personnel, 132 technical personnel, and 21 sales personnel[180]. - The company emphasizes employee training and development, implementing a systematic training program that includes both pre-job and on-the-job training[183]. Strategic Initiatives - The company plans to implement a matrix marketing network and improve customer service responsiveness to enhance market share and customer satisfaction[1][2]. - The company is considering future refinancing options, including issuing stocks or bonds, to meet its development needs while managing financial risks[1][2]. - The company plans to invest in the production of flavoring agents and food additives, with a target capacity of 6,500 tons per year[112].

亚香股份（301220）公告，2024年营业收入7.97亿元，同比增长26.42%。归属于上市公司股东的净利润 5570.3万元，同比下降30.51%。公司拟向全体股东每10股派发现金红利2元(含税)，送红股0股(含税)， 以资本公积金向全体股东每10股转增4股。 ...

化工板块反复活跃 红墙股份3连板 智通财经4月21日电，红墙股份、尤夫股份走出3连板，中毅达走出8天4板，亚香股份、丹化科技、山东 海化、江天化学等涨幅靠前。消息面上，截至4月17日，A股共有31家化工上市公司披露一季度业绩预 告，全部预喜，其中21家预增。整体来看，产品价格上涨、结构优化等是化工行业上市公司一季度取得 较好业绩的主要因素。 ...

Investment Rating - The report does not explicitly state an investment rating for the synthetic biology industry Core Insights - The synthetic biology sector is experiencing a global technological revolution, providing innovative solutions to major challenges such as health, climate change, and food security, as highlighted by the National Development and Reform Commission's "14th Five-Year Plan for Bioeconomic Development" [4] - The Huazhong Securities synthetic biology index, which includes 58 companies across various sectors, has seen a decline of 9.66% recently, underperforming compared to the Shanghai Composite Index [5][17] Industry Market Dynamics - The synthetic biology sector's stocks have performed poorly recently, with a 9.66% drop, ranking 32nd among sectors [17] - The top five gainers in the synthetic biology sector include: - Novozymes (+27%) - Shandong Heda (+10%) - Yaxiang Co. (+10%) - Pro Pharma (+3%) - Huafeng Chemical (+2%) [18] - The top five losers include: - Xinri Hengli (-18%) - Kasei Biotech (-12%) - Yabao Chemical (-9%) - Berry Genomics (-7%) - Weilan Bio (-6%) [22] Company Business Developments - Anhui Pucan has launched the world's largest CO₂-based polycarbonate production facility, with an annual capacity of 50,000 tons, expected to generate sales of 1.5 billion yuan [23] - Huafeng Chemical plans to acquire two subsidiaries to integrate its polyurethane supply chain, with projected revenues exceeding 6.4 billion yuan in 2024 [23] - Tianchen Company signed a contract for a 100,000 tons/year bioethanol project in Egypt, marking its first venture into the North African market [24] - Kosemet announced a partnership with Shanghai Xinhai Biotechnology to develop bio-synthesized retinol for skincare products [25] Industry Financing Tracking - The synthetic biology sector has seen accelerated financing, with nearly 100 companies completing new funding rounds since the beginning of 2025 [28] - Zhongsheng Suyuan Biotechnology completed a B round financing of 235 million yuan, focusing on iPSC-derived cell therapies [28] - Korean company INTAKE raised approximately 9.2 million USD in a C round financing to develop precision fermentation proteins [29] Company R&D Directions - Jinbo Biotech received approval for its recombinant type III human collagen injection product, marking a breakthrough in high-end medical aesthetics [31] - CellX's mushroom protein received FDA GRAS certification, allowing it to enter the U.S. market [31] - MycoTechnology's truffle sweet protein product received FEMA GRAS certification, showcasing advancements in natural flavoring solutions [32] - Nourish Ingredients and Cabio Biotech successfully commercialized a precision fermentation fat product, enhancing the flavor of plant-based products [34]

Investment Rating - The report does not explicitly state an investment rating for the synthetic biology industry Core Insights - The synthetic biology sector is experiencing a global revolution, integrating into economic and social development to address major challenges such as health, climate change, and food security. The National Development and Reform Commission has issued the "14th Five-Year Plan for Bioeconomic Development," indicating a trillion-yuan market potential in the bioeconomy [4] Industry Market Dynamics - The synthetic biology index decreased by 9.66% to 1437.31 during the week of April 5-11, 2025, underperforming compared to the Shanghai Composite Index, which fell by 1.62%, and the ChiNext Index, which dropped by 4.21% [5][17] - The top five performing companies in the synthetic biology sector during this period were: - Novozymes (+27%) - Shandong Heda (+10%) - Yaxing Co. (+10%) - Pro Pharma (+3%) - Huafeng Chemical (+2%) [18] - The bottom five performing companies were: - Xinri Hengli (-18%) - Kasei Biotech (-12%) - Yaborn Chemical (-9%) - Berry Genomics (-7%) - Blue Biological (-6%) [22] Company Business Developments - Anhui Pucan launched the world's largest CO₂-based polycarbonate production facility, with an annual capacity of 50,000 tons, expected to generate sales of 1.5 billion yuan [23] - Huafeng Chemical plans to acquire two subsidiaries to integrate the polyurethane supply chain, with projected combined revenue exceeding 6.4 billion yuan in 2024 [23] - Tianchen Company signed a contract for a 100,000 tons/year bioethanol project in Egypt, marking its first venture into the North African market [24] Industry Financing Tracking - Synthetic biology companies are accelerating financing, with nearly 100 firms completing new rounds of funding since the beginning of 2025. Zhongsheng Suyuan Biotechnology raised 235 million yuan in its B round, focusing on iPSC-derived cell therapies [28][29] Company R&D Directions - Jinbo Biotech received approval for its recombinant type III human collagen injection product, marking a breakthrough in high-end medical aesthetics [31] - CellX's mushroom mycelium protein received FDA GRAS certification, allowing entry into the U.S. market [31] - MycoTechnology's truffle sweet protein ClearHT received FEMA GRAS certification, showcasing advancements in natural flavoring and health foods [32]

昆山亚香香料股份有限公司（以下简称"公司"）第三届董事会、监事会及高级 管理人员任期于 2025 年 4 月 10 日届满，公司正在积极筹备换届工作。鉴于公司新一 届董事、监事及高级管理人员候选人的提名工作仍在进行中，为保持相关工作的准确 性、连续性和稳定性，公司董事会、监事会换届选举工作将适当延期，公司董事会各 专门委员会委员和高级管理人员的任期也将相应顺延。公司将积极推进董事会、监事 会及高级管理人员的换届选举工作，并在相关事宜确定后，及时履行相应的信息披露 义务。 证券代码：301220 证券简称：亚香股份 公告编号：2025-014 昆山亚香香料股份有限公司 关于董事会、监事会和高级管理人员延迟换届的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 在换届选举工作完成之前，公司第三届董事会、监事会全体成员及高级管理人员 将依照法律、行政法规和《公司章程》等相关规定，继续履行该届董事、监事及高级 管理人员的义务与职责。公司董事会、监事会及高级管理人员的延迟换届不会影响公 司的正常经营。 特此公告。 昆山亚香香料股份有限公司 董事会 2025 年 4 ...

Core Viewpoint - The recent series of share reduction announcements by major shareholders and executives of Yaxiang Co., Ltd. has raised concerns about the company's future development amidst declining performance metrics [1][2]. Group 1: Share Reduction Details - Major shareholder Kunshan Dinglong Bohui Investment Management plans to reduce its holdings by up to 2.424 million shares, accounting for 3% of the total share capital, within 90 days after the announcement [1]. - Executives including the board secretary and several directors also plan to reduce their holdings, with a total reduction of 0.35% [1]. - The timing of these reductions coincides with the company's stock price being at historical highs, suggesting that the reductions may be a strategy to lock in profits [1][2]. Group 2: Company Performance - In 2023, Yaxiang Co., Ltd. experienced a 10.66% decline in revenue and a 39.18% drop in net profit [2]. - For the first three quarters of 2024, the company reported a revenue increase of 21.37% to 576 million yuan, but the net profit attributable to shareholders fell by 34.58%, indicating a situation of increasing revenue without corresponding profit growth [2]. - The significant drop in performance metrics may contribute to the shareholders' decision to reduce their stakes, reflecting concerns about the company's future prospects [2]. Group 3: Market Reaction and Implications - Following the announcements, Yaxiang Co., Ltd.'s stock price fell by over 11% during intraday trading on April 3, indicating a negative market reaction [2]. - The concentrated share reduction may lead to increased volatility in the stock price and could raise questions about the company's internal governance and future development [2][3]. - The company is urged to focus on enhancing its core competitiveness and improving performance to regain market confidence [3].